187 related articles for article (PubMed ID: 11818148)
21. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses.
Liu LJ; Watabe S; Yang J; Hamajima K; Ishii N; Hagiwara E; Onari K; Xin KQ; Okuda K
Vaccine; 2001 Oct; 20(1-2):42-8. PubMed ID: 11567744
[TBL] [Abstract][Full Text] [Related]
22. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.
Moore AC; Kong WP; Chakrabarti BK; Nabel GJ
J Virol; 2002 Jan; 76(1):243-50. PubMed ID: 11739689
[TBL] [Abstract][Full Text] [Related]
23. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.
Belyakov IM; Moss B; Strober W; Berzofsky JA
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4512-7. PubMed ID: 10200293
[TBL] [Abstract][Full Text] [Related]
24. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
25. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.
Chakrabarti BK; Kong WP; Wu BY; Yang ZY; Friborg J; Ling X; King SR; Montefiori DC; Nabel GJ
J Virol; 2002 Jun; 76(11):5357-68. PubMed ID: 11991964
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
[TBL] [Abstract][Full Text] [Related]
27. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
28. Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly(DL-lactide-co-glycolide) microparticles.
Moureau C; Vidal PL; Bennasser Y; Moynier M; Nicaise Y; Aussillous M; Barthelemy S; Montagnier L; Bahraoui E
Mol Immunol; 2002 Jan; 38(8):607-18. PubMed ID: 11792429
[TBL] [Abstract][Full Text] [Related]
29. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity.
Singh M; Vajdy M; Gardner J; Briones M; O'Hagan D
Vaccine; 2001 Nov; 20(3-4):594-602. PubMed ID: 11672926
[TBL] [Abstract][Full Text] [Related]
30. Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.
Peacock JW; Nordone SK; Jackson SS; Liao HX; Letvin NL; Yafal AG; Gritz L; Mazzara GP; Haynes BF; Staats HF
J Virol; 2004 Dec; 78(23):13163-72. PubMed ID: 15542668
[TBL] [Abstract][Full Text] [Related]
31. Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.
Kiszka I; Kmieciak D; Gzyl J; Naito T; Bolesta E; Sieron A; Singh SP; Srinivasan A; Trinchieri G; Kaneko Y; Kozbor D
J Virol; 2002 May; 76(9):4222-32. PubMed ID: 11932387
[TBL] [Abstract][Full Text] [Related]
32. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.
Bolesta E; Kowalczyk A; Wierzbicki A; Eppolito C; Kaneko Y; Takiguchi M; Stamatatos L; Shrikant PA; Kozbor D
J Immunol; 2006 Jul; 177(1):177-91. PubMed ID: 16785513
[TBL] [Abstract][Full Text] [Related]
33. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
Fuller DH; Haynes JR
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
[TBL] [Abstract][Full Text] [Related]
34. An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice.
Brühl P; Kerschbaum A; Eibl MM; Mannhalter JW
AIDS Res Hum Retroviruses; 1998 Mar; 14(5):401-7. PubMed ID: 9546799
[TBL] [Abstract][Full Text] [Related]
35. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
[TBL] [Abstract][Full Text] [Related]
37. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
Muthumani K; Zhang D; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB
Virology; 2003 Sep; 314(1):134-46. PubMed ID: 14517067
[TBL] [Abstract][Full Text] [Related]
38. Anti-HIV env immunities elicited by nucleic acid vaccines.
Shiver JW; Davies ME; Yasutomi Y; Perry HC; Freed DC; Letvin NL; Liu MA
Vaccine; 1997 Jun; 15(8):884-7. PubMed ID: 9234539
[TBL] [Abstract][Full Text] [Related]
39. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses.
Gzyl J; Bolesta E; Wierzbicki A; Kmieciak D; Naito T; Honda M; Komuro K; Kaneko Y; Kozbor D
Virology; 2004 Jan; 318(2):493-506. PubMed ID: 14972518
[TBL] [Abstract][Full Text] [Related]
40. Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine.
Isshiki M; Zhang X; Sato H; Ohashi T; Inoue M; Shida H
Vaccine; 2014 Feb; 32(7):839-45. PubMed ID: 24370703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
